Ann Marie Burke, APRN
Psychiatric/Mental Health · Leesburg, FLNPI 1801364377
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 470 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 470 payments — averaging $30.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- plus $5K from 23 others
What the payments were for
- Food & beverage$14,215100%
- Education$570%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 104 | $2,119 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $1,672 |
| Otsuka America Pharmaceutical, Inc. | 38 | $1,535 |
| Neurocrine Biosciences, Inc. | 52 | $1,497 |
| Alkermes, Inc. | 33 | $1,266 |
| Vanda Pharmaceuticals Inc. | 25 | $1,247 |
| E.r. Squibb & Sons, L.L.C. | 13 | $751 |
| AbbVie | 53 | $740 |
| Axsome Therapeutics, Inc. | 11 | $583 |
| Johnson & Johnson | 8 | $373 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $348 |
| Corium, LLC | 12 | $313 |
| Paratek Pharmaceuticals, Inc. | 2 | $226 |
| Indivior Inc. | 9 | $214 |
| Idorsia Pharmaceuticals US Inc | 12 | $212 |
| Sunovion Pharmaceuticals Inc. | 12 | $211 |
| Sanofi | 1 | $122 |
| Gilead | 1 | $115 |
| Genentech USA, Inc. | 1 | $102 |
| AstraZeneca | 1 | $98 |
| Lundbeck LLC | 5 | $98 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $90 |
| Bayer | 1 | $89 |
| Lilly USA, LLC | 1 | $80 |
| Supernus Pharmaceuticals, Inc. | 5 | $79 |
| Acadia Pharmaceuticals Inc | 1 | $45 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Medline Industries LP | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$923
- Fanapt$707
- CAPLYTA$628
- ABILIFY MAINTENA$570
- ARISTADA$488
- Auvelity$461
- COBENFY$363
- ABILIFY ASIMTUFII$327
- REXULTI$244
- Austedo XR$236
- INGREZZA$233
- NUZYRA$226
- VRAYLAR$219
- SPRAVATO$146
- AUSTEDO$140
- OPDIVO$126
- Azstarys$125
- FABRAZYME$122
- ARISTADA INITIO$122
- QUVIVIQ$119
How this compares
$14,272 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 66 | $725,985 |
| Invega SustennaPaliperidone Palmitate | 98 | $331,277 |
| IngrezzaValbenazine Tosylate | 31 | $258,947 |
| RexultiBrexpiprazole | 137 | $221,561 |
| Invega TrinzaPaliperidone Palmitate | 17 | $175,308 |
| VraylarCariprazine Hcl | 94 | $141,152 |
| Abilify AsimtufiiAripiprazole | 22 | $128,411 |
| Abilify MaintenaAripiprazole | 42 | $121,834 |
| AristadaAripiprazole Lauroxil | 21 | $77,132 |
| LybalviOlanzapine/Samidorphan Malate | 39 | $62,386 |
| CaplytaLumateperone Tosylate | 29 | $51,580 |
| Risperdal ConstaRisperidone Microspheres | 25 | $43,888 |
| PerserisRisperidone | 14 | $40,851 |
| BelsomraSuvorexant | 76 | $34,146 |
| TrintellixVortioxetine Hydrobromide | 43 | $27,836 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,119 | $725,98566 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $373 | $550,472140 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Asimtufii, Abilify Maintena | $1,535 | $471,806201 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,497 | $258,94731 claims |
| AbbVieVraylar | $740 | $141,15294 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,266 | $139,51760 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,672 | $51,58029 claims |
| Indivior Inc.Perseris | $214 | $40,85114 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $348 | $27,83643 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $212 | $13,15427 claims |
| Axsome Therapeutics, Inc.Auvelity | $583 | $12,09321 claims |
| Lilly USA, LLCOlanzapine | $80 | $2,439124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Leesburg
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
- Carolann BrooksCelebration$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.